Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 8, 2009

Cell Biosciences Purchases Alpha Innotech for $17.9M

  • Cell Biosciences is taking over Alpha Innotech for $17.9 million in cash. This acquisition expands the company’s protein-analysis business to include a global infrastructure and a larger product portfolio.

    Cell Biosciences will pay $1.50 per share, a 70.45% premium over Alpha Innotech’s closing price yesterday. Cell Biosciences will also assume $2.1 million of outstanding debt, net of cash. Cell Biosciences entered into agreements to raise an additional $19 million in cash in a Series C and a Series D preferred stock financing.

    Directors, executive officers, and certain stockholders of Alpha Innotech, who collectively hold approximately 33% of Alpha Innotech's outstanding common stock, have agreed to vote in favor of the transaction. The parties expect the transaction to be completed in approximately 60 days.

    Alpha Innotech uses high-sensitivity digital imaging systems for genomic and proteomic research. The company offers a range of products from entry-level gel documentation systems to systems for multiplexed fluorescence and proteomics applications. The company has sold over 10,000 systems worldwide. In 2008 the firm achieved revenues of $17.6 million and was profitable on both an operating and a net income basis. Alpha Innotech employs 62 people, primarily at its San Leandro, CA, headquarters.

    Cell Biosciences’ lead product is the CB1000, a nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of oncoproteins and other signaling proteins in ultra-small biological samples. It is headquartered in Santa Clara, CA, and has 49 employees located in North America and Europe.


Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »